← Back to headlines
CRISPR (CRSP) Receives 'Overweight' Rating Amid Gene Editing Growth
CRISPR Therapeutics (CRSP) has been rated 'Overweight' by analysts, reflecting positive sentiment regarding the company's growth prospects in gene editing.
31 Mar, 08:46 — 31 Mar, 08:46
Sources
Showing 1 of 1 sources
Related Stories
Lionel Richie Hospitalized in ICU Following St. Louis Concert
23m ago
Anna Hazare admitted to Mumbai hospital's ICU with acute dehydration, kidney issue
7h ago
Ebola Outbreak in Democratic Republic of Congo Surpasses 6,000 Cases
9h ago
England Pharmacies to Offer Free Quick Cholesterol Screening Tests
18h ago